Effect of demographic characteristics on the outcome of prostate cancer salvage radiotherapy: Analysis from a randomized controlled trial.

CancerSep 15, 2026
Clinical ResearchOncology (Medical)

Ismaheel O Lawal, Ashesh B Jani, Subir Goyal et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial examined the effects of demographic factors on salvage radiotherapy (sRT) outcomes in post-prostatectomy men with detectable PSA. The study found that African American men (AAM) had a higher failure-free survival (FFS) rate compared to men of other races (MOR), with rates of 72.8% vs 58.7% (p = .002).

Key findings

  • AAM had a higher FFS rate than MOR, 72.8% vs 58.7% (p = .002).
  • In arm A, AAM's FFS rate was 64.0% compared to 45.3% for MOR (p = .008).
  • In arm B, FFS improved for both groups, with AAM at 81.5% and MOR at 73.0% (p = .131).
  • AAM had lower socioeconomic status and higher allostatic load scores than MOR.

Why it matters

Understanding the impact of demographic characteristics on treatment outcomes can help clinicians tailor interventions and address disparities in care for prostate cancer patients, particularly in salvage radiotherapy settings.

Source

Published in Cancer. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.